Order;Information — ECLI:EU:T:2023:417
Date: 2023-07-21
Language of the case: English
Court formation: President of the Chamber
Subject matter: Provisions governing the Institutions;Access to documents
Procedure: Action for annulment;Application for interim measures - successful
Origin: France

Order of the President of the General Court of 21 July 2023 – Arysta Lifescience v EFSA (Case T-222/23 R) (Interim relief – Access to documents – Regulation (EC) No 1049/2001 – Documents related to the procedure for renewing the approval of an active substance – Documents originating from a third party – Decision to grant a third party access to the documents – Application for suspension of operation of a measure – Concept of ‘information relating to emissions into the environment’ – Regulation (EC) No 1367/2006 – Prima facie case – Urgency – Balancing of competing interests) Language of the case: English Parties Applicant: Arysta Lifescience (Noguères, France) (represented by: D. Abrahams, Z. Romata, H. Widemann and R. Spangenberg, lawyers) Defendant: European Food Safety Authority (EFSA) (represented by: D. Detken, S. Gabbi and C. Pintado, acting as Agents, and by S. Raes, J. Degrooff, and E. Kairis, lawyers) Re: By its application on the basis of Articles 278 and 279 TFEU, the applicant seeks the suspension of operation of the decision of the European Food Safety Authority (EFSA) of 17 February 2023 notifying it of the full disclosure of the list of co-formulants present in the formulation for representative uses of Captan 80 WG submitted in the framework of the renewal of the approval of the active substance Captan. Operative part of the order Operation of the decision of the European Food Safety Authority (EFSA) of 17 February 2023 notifying Arysta Lifescience of the full disclosure of the list of co-formulants present in the formulation for representative uses of Captan 80 WG submitted in the framework of the renewal of the approval of the active substance Captan is suspended. The costs are reserved. The order of 8 May 2023, Arysta Lifescience v EFSA (T-222/23 R) is set aside. ____________